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Abstract
Five somatostatin receptor (sst) subtype genes, sst1, sst2, sst3, sst4 and sst5, have been cloned and
characterised. The five sst subtypes all bind natural somatostatin-14 and somatostatin-28 with high
affinity. Endocrine pancreatic and endocrine digestive tract tumours also express multiple sst
subtypes, but sst2 predominance is generally found. However, there is considerable variation in sst
subtype expression between the different tumour types and among tumours of the same type. The
predominant expression of sst2 receptors on pancreatic endocrine or carcinoid tumours is essential for
the control of hormonal hypersecretion by the octapeptide somatostatin analogues such as octreotide
and lanreotide. Somatostatin and its octapeptide analogues are also able to inhibit proliferation
of normal and tumour cells. The high density of sst2 or sst5 on pancreatic endocrine or carcinoid
tumours further allows the use of radiolabelled somatostatin analogues for in vivo visualisation. The
predominant expression of sst2 receptors in these tumours and the efficiency of sst2 receptors to
undergo agonist-induced internalisation is also essential for the application of radiolabelled
octapeptide somatostatin analogues. Currently, [111In-DTPA0]octreotide, [90Y-DOTA0,Tyr3]octreotide,
[177Lu-DOTA0Tyr3]octreotate, [111In-DOTA0]lanreotide and [90Y-DOTA0]lanreotide can be used for this
purpose.
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Somatostatin
Somatostatin is a small cyclic peptide. It circulates in the
blood in two biologically active forms: somatostatin-14, con-
sisting of 14 amino acids and somatostatin-28, consisting of
28 amino acids (Reichlin 1983a,b). Somatostatin is formed
by proteolytic processing of larger precursor molecules:
prepro-somatostatin and pro-somatostatin. This peptide was
detected accidentally during studies of the distribution of
growth hormone-releasing factor in the hypothalamus of rats
(Krulich et al. 1968, Brazeau et al. 1973). Somatostatin
inhibits a variety of physiological functions in the gastroin-
testinal tract, such as gastrointestinal motility, gastric acid
production, pancreatic enzyme secretion, bile secretion and
colonic fluid secretion. It also inhibits the secretion of pan-
creatic and intestinal hormones such as insulin, glucagon,
secretin and vasoactive intestinal polypeptide. In addition to
playing an important regulatory role in neurotransmission
and secretion, the peptide may control cell proliferation in
normal tissues and tumours (Reichlin 1983a,b, Schally 1988,
Lamberts et al. 1991). In view of the ability of somatostatin
to inhibit such a variety of physiological processes, it was
predicted that this peptide might be of therapeutic value in
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clinical conditions involving hyperfunction or hypersecretion
of the organ systems mentioned above. However, the mul-
tiple simultaneous effects of pharmacological concentrations
of somatostatin in different organs, the need for intravenous
administration, the short duration of action (a half-life in the
circulation of less than 3 min) and the post-infusion rebound
hypersecretion of hormones considerably hampered the
initial enthusiasm, as well as its clinical use (Lamberts et al.
1996).
Somatostatin receptor subtypes
Somatostatin-14 and somatostatin-28 act through high-
affinity G protein-coupled membrane receptors. Five somato-
statin receptor (sst) subtype genes have been cloned and
characterised. They were code-named sst1, sst2, sst3, sst4 and
sst5 (Hoyer et al. 1994). The genes encoding the five sst sub-
types are localised on different chromosomes (Patel 1997).
Two forms of the sst2 receptor (sst2A and sst2B) can be gener-
ated through alternative splicing (Vanetti et al. 1992, Patel
et al. 1993). Upon binding of somatostatin to its receptor
subtype(s) second messenger systems will become activated.
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Table 1 Binding affinities of somatostatin analogues to the five sst subtypes (Bruns et al. 2002). Values are means ± S.E.M.
Compound IC50 value (nM)
sst1 sst2 sst3 sst4 sst5
Somatostatin 14 0.93 ± 0.12 0.15 ± 0.02 0.56 ± 0.17 1.5 ± 0.4 0.29 ± 0.04
Lanreotide 180 ± 20 0.54 ± 0.08 14 ± 9 230 ± 40 17 ± 5
Octreotide 280 ± 80 0.38 ± 0.08 7.1 ± 1.4 >1000 6.3 ± 1.0
Chromosomal location 14 17 22 20 16
These systems include (1) inhibition of adenylate cyclase
activity and (2) activity of calcium channels, as well as (3)
stimulation of phosphotyrosine phosphatase or (4) MAP
(mitogen-activated protein) kinase activity (Reisine & Bell
1995, Patel 1997, 1999). The inhibitory effects of somatosta-
tin on adenylate cyclase activity and on the influx of calcium
are linked to inhibition of secretion processes. The activation
of phosphotyrosine phosphatase or MAP kinase activity by
somatostatin may play a role in the regulation of cell prolifer-
ation (Schally 1988, Lamberts et al. 1991, Hofland et al.
1995).
Classical somatostatin-target tissues such as the central
nervous system, the anterior pituitary gland and the pancreas
express multiple sst subtypes. Pancreatic islet cells express
all five sst subtype proteins (Reubi et al. 1998b, Kumar et
al. 1999). In these cells, sst1, sst2 and sst5 receptors are the
most abundantly expressed subtypes, with a high percentage
of β-cells expressing sst1 and sst5, α-cells expressing sst2 and
δ-cells expressing sst5 (Kumar et al. 1999).
Tumours arising from somatostatin-target tissues fre-
quently express a high density of ssts (Reubi et al. 1992a,b,
1994, 1996, 2001). The sst-expressing tumours include pitu-
itary adenomas, pancreatic endocrine tumours, carcinoids,
paragangliomas, pheochromocytomas, small cell lung can-
cers, medullary thyroid carcinomas, breast cancers and
malignant lymphomas (Reubi et al. 1992b, Vikic-Topic et al.
1995). The sst subtype expression in different tumours has
been demonstrated at the mRNA level using in situ hybridis-
ation, RNase protection assays and RT-PCR (Kubota et al.
1994, Panetta & Patel 1995). The majority of sst-positive
tumours simultaneously express multiple sst subtypes,
although there is a considerable variation in sst subtype expres-
sion between the different tumour types and among tumours of
the same type (Reubi et al. 1998a, Schulz et al. 1998, Kimura
et al. 1999, Hofland et al. 1999b). Endocrine pancreatic and
endocrine digestive tract tumours can also express multiple
sst subtypes, but sst2 predominance is generally found in
more than 80% (Reubi et al. 1994, 2001, de Herder et al.
1996a, Papotti et al. 2002, Reubi & Waser 2003).
The five sst subtypes all bind somatostatin-14 and soma-
tostatin-28 with high affinity. The sst1 and sst4 receptors do
not bind the currently available octapeptide somatostatin ana-
logues octreotide and lanreotide (see later), whereas sst2A, sst3
and sst5 receptors display a high, low, and moderate affinity
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respectively towards these octapeptide somatostatin analogues
(Table 1). The predominant expression of sst2 receptors on
pancreatic endocrine or carcinoid tumours forms the basis for
the successful clinical application of octapeptide somatostatin
analogues such as octreotide and lanreotide in controlling
symptoms related to hormonal hypersecretion (Lamberts et al.
1996, de Herder et al. 1996b, de Herder & Lamberts 2002).
The high density of sst subtypes on these tumours further
allows the use of radiolabelled somatostatin analogues to
visualise sst-positive tumours in vivo (see later) (Krenning
et al. 1992, 1993, 1994a,b, 1999, Kwekkeboom et al. 1993,
Kwekkeboom & Krenning 1996). Therefore, knowledge of
the sst subtype expression patterns in endocrine tumours may
be very important for the development of the concept of sst-
targeted radiotherapy or chemotherapy (see later).
Also, ssts may form homo- or heterodimers or may heter-
odimerise with other G protein-coupled receptors such as the
dopamine D2 receptor or the µ-opioid receptor (MOR-1),
resulting in a novel receptor state with properties different
from the individual receptors (Rocheville et al. 2000a,b,
Pfeiffer et al. 2001, 2002).
Somatostatin analogues
As mentioned above, there are several limitations to the use
of native somatostatin-14 and -28 in daily practice. There-
fore, attempts have been made to synthesise somatostatin
analogues for clinical use. Octreotide (Sandostatin, Novartis,
Basel, Switzerland) was the first octapeptide somatostatin
analogue that was synthesised. Its elimination half-life after
subcutaneous administration is 2 h, and rebound hypersecre-
tion of hormones does not occur (Bauer et al. 1982). Somato-
statin and its analogues exert their effects through interaction
with sst subtypes 1 through 5 (sst1–5). Somatostatin binds
with high affinity to all somatostatin subtypes, whereas octre-
otide binds only with a high affinity to sst2 and sst5 (Patel
1999). Other cyclic analogues with almost similar affinity
and activity profiles, such as lanreotide (Somatuline, Ipsen
Biotech, Paris, France) have been subsequently developed
(Lamberts et al. 1996). Octreotide (Sandostatin) and lanreo-
tide (Somatuline) have been registered in most countries for
the control of hormonal symptoms in patients with carcinoids
and endocrine pancreatic tumours and in patients with acro-
megaly. Octreotide and lanreotide can be administered by
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multiple subcutaneous injections or by continuous subcutane-
ous infusion as well as by the intravenous route, either as a
single injection or as a continuous infusion over many hours
or days. The slow-release depot intramuscular formulation of
octreotide (Sandostatin LAR, Novartis Pharma, Basel,
Switzerland) has to be administered once every 4 weeks and
that of lanreotide (Somatuline-PR, Ipsen Biotech, Paris,
France) once every 2 weeks. A new slow-release depot
preparation of lanreotide, Lanreotide Autogel (Ipsen Biotech,
Paris France), has been introduced in several European
countries. This drug has to be administered deep subcutane-
ously once every 4 weeks.
In the majority of patients with metastatic carcinoids and
pancreatic endocrine tumours, treatment with octreotide
induces a rapid improvement of clinical symptomatology,
such as diarrhoea, dehydration, flushing attacks, hypokalae-
mia, peptic ulceration, hypoglycaemic attacks and necrotic
skin lesions (Kvols et al. 1986, 1987, Ruszniewski et al.
1996, Caplin et al. 1998, Kulke & Mayer 1999, Wymenga
et al. 1999). On the other hand, the majority of these patients
show desensitisation of the inhibition of hormone secretion
by octreotide and lanreotide within weeks to months. In a
series of 57 patients with the carcinoid syndrome, octreotide
therapy was ended in 23 patients after periods ranging from
1 week to 12.5 months (median 4 months), whereas the other
responding patients could be controlled for periods extending
to 2.5 years. The estimated mean duration of response to
octreotide therapy in the whole group of responding patients
was approximately 1 year (Moertel 1987). The potential
mechanisms responsible for this desensitisation, as well as
for the considerable variability in the duration of the
responses to octreotide therapy are not known at present.
Potential mechanisms of tachyphylaxis and resistance to
somatostatin analogue therapy in patients with sst-positive
tumours are (1) receptor down-regulation; a decrease in the
number and/or affinity of ssts, (2) desensitisation; a decrease
in responsiveness due to receptor uncoupling from second
messenger activation, (3) non-homogeneous expression of
ssts in tumours, (4) outgrowth of sst-negative cell clones, (5)
resistance due to the absence of sst subtypes with high affin-
ity for octapeptide somatostatin analogues, (6) resistance due
to tachyphylaxis of the inhibitory effect of somatostatin ana-
logues on indirect tumour growth-promoting mechanisms
(like growth hormone or gastrin) and (7) mutations in sst
genes leading to the absence of functional receptor proteins
(Lamberts et al. 1988, Hofland & Lamberts 2003).
Expression of ssts by endocrine tumours is essential for
the control of hormonal hypersecretion by the octapeptide
somatostatin analogues. Somatostatin is also able to inhibit
proliferation of normal and tumour cells. Induction of G1
cell arrest and induction of apoptosis have been demonstrated
in a number of tumour cell models and several sst subtypes
seem to be involved (Buscail et al. 1994, 1995, Cordelier et
al. 1997, Alderton et al. 1998, Bousquet et al. 1998, 2001,
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Sharma & Srikant 1998, Sharma et al. 1999, Pages et al.
1999, Rochaix et al. 1999, Benali et al. 2000, Vernejoul et
al. 2002b). Various reports demonstrating tumour regression
or stabilisation in patients with metastatic carcinoids and
endocrine tumours of the gastrointestinal tract with octapep-
tide somatostatin analogues are consistent with these exper-
imental data although other mechanisms may also play a role,
such as inhibition of angiogenesis and inhibition of growth
factors by these drugs (Kraenzlin et al. 1983, Clements &
Elias 1985, Wiedenmann et al. 1988, Woltering et al. 1997,
Filosso et al. 2000, Imtiaz et al. 2000, Delle Fave & Corleto
2001, Garcia de la Torre et al. 2002, Shojamanesh et al.
2002, Florio et al. 2003).
sst scintigraphy
Tumours and metastases that bear sst2 or sst5 can be visual-
ised in vivo after injection of radiolabelled octapeptide
analogues. The technique of sst scintigraphy to visualise
sst-positive tumours in man was first developed using the
radiolabelled somatostatin analogue [123I-Tyr3]octreotide
(Krenning et al. 1989). Because the use of this radiopharma-
ceutical had a number of drawbacks (such as costs, lack of
availability, short physical half-life and predominant hepatic
clearance resulting in accumulation of radioactivity in liver,
gall bladder, bile ducts and gastrointestinal tract), novel som-
atostatin analogues were developed to circumvent these
disadvantages. The most widely used somatostatin analogue
for sst scintigraphy is currently 111In-pentetreotide
([111In-DTPA0]octreotide, OctreoScan, Tyco Healthcare,
Mallickrodt, St Louis, USA) (Krenning et al. 1993). Apart
from 111In-pentetreotide, [111In-DOTA0]lanreotide can also be
used (Krenning et al. 1994b, Virgolini et al. 2001).
sst targeted radiotherapy
In general, sst–agonist complexes follow the mechanism and
route of internalisation as described for many other G pro-
tein-coupled receptor complexes (Hausdorff et al. 1990, Yu
et al. 1993, Roettger et al. 1995, Ferguson et al. 1996,
Koenig & Edwardson 1997, Hofland & Lamberts 2003). The
sst subtypes differentially internalise somatostatin and
somatostatin analogues. The sst1 receptors show low agonist-
induced internalisation, whereas sst2, sst3, sst4 and sst5 are
more efficient in this respect (Patel 1999, Hofland & Lam-
berts 2003).
In tumour tissue obtained after the administration of
[111In-DTPA0]octreotide to patients harbouring Octreoscan-
positive metastatic midgut carcinoids, the subcellular distri-
bution of radioactivity using ultrastructural autoradiography
was subsequently analysed. This radioactivity could be found
at the plasma membrane, in the cytoplasmic areas among
secretory granules and vesicular compartments, but also in
the perinuclear area. This localisation of 111In in close prox-
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imity to the cell nucleus is especially important for this short
range Auger electron-emitting radioisotope to exert its cyto-
toxic effect in the form of DNA double-strand damage
(Janson et al. 2000). The predominant expression of sst2
receptors in most sst-positive endocrine tumours and the
efficiency of sst2 receptors to undergo agonist-induced intern-
alisation is very important for the application of sst-targeted
radiotherapy. However, [111In-DTPA0]octreotide may not be
the most suitable compound to carry out radiotherapy
because the Auger electron-emitter 111In has a low tissue
penetration. In addition, a stable coupling of α- or β-emitting
isotopes to [DTPA0]octreotide could not be achieved, which
initiated the development of a novel compound, such as
[DOTA0,Tyr3]octreotide, allowing a stable binding with the
β-emitter yttrium-90 (90Y) [90Y-DOTA0,Tyr3]octreotide
(OctreoTher, Novartis Pharma, Basel, Switzerland) and lute-
tium 177 ([177Lu-DOTA0Tyr3]octreotate). Furthermore, [111In-
DOTA0]lanreotide and [90Y-DOTA0]lanreotide can also be
used for radiotherapy of sst2- and sst5-positive advanced or
metastatic endocrine tumours (Hofland et al. 1999a, Anthony
et al. 2002, Kwekkeboom et al. 2002, 2003, Valkema et al.
2002a,b, Virgolini et al. 2002).
Several mechanisms may determine the amount of
uptake of radiolabelled somatostatin analogues. These
include: (1) the stability of the radioligand, (2) the density of
sst expression on the tumour, (3) the type of ssts expressed
by the tumour, (4) affinity of the radioligand for the sst, (5)
the efficiency of sst-mediated internalisation and recycling,
(6) the final trapping of the radioisotopes within the tumour
cells, as well as (7) the mass of the injected peptide (Nouel
et al. 1997, Hukovic et al. 1999, Hofland 1999a, Hofland &
Lamberts 2003).
New developments
Because every sst has distinct biologic functions, the develop-
ment of new classes of somatostatin subtype-selective
analogues may provide valuable information for tumour
diagnosis, prognosis and prediction of somatostatin analogue
efficacy, not only in tumours that are sensitive to the cur-
rently available octapeptide analogues, but also in tumours
that express ssts other than sst2 and sst5. A new so-called
‘universal’ somatostatin analogue, named SOM230, with
high affinity for sst1, sst2, sst3 and sst5 receptors is currently
under evaluation in phase I–III trials (Bruns et al. 2002,
Lamberts et al. 2002, Weckbecker et al. 2002). New
drugs interacting with multi-receptor family cross-talk are
being developed. These sst subtype homo- or heterodimers
may have properties which are distinct from the individual
receptors in terms of internalisation, agonist-induced desensi-
tisation and functional activity (Rocheville et al. 2000a,b,
Pfieffer et al. 2001, 2002). The hybrid somatostatin–dopamine
molecule, BIM-23A387, has high-affinity binding to both sst2
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and dopamine D2 receptors and has an enhanced potency on
growth hormone and prolactin release by primary cultures of
pituitary adenoma cells, compared with sst2- and D2-specific
analogues alone or in combination. This significant enhanced
potency, however, cannot be explained on the basis of the
binding affinity of the compounds for sst2 and dopamine D2
receptors (Saveanu et al. 2002).
Like peptide receptor-targeted radiotherapy, targeted
chemotherapy to deliver the chemotherapeutic compounds
selectively to tumour cells might be a promising approach as
well (Plonowski et al. 2000, 2001, 2002, Kiaris et al. 2001).
Although still at a very early stage, gene therapy may repre-
sent an exciting new treatment alternative for patients with
advanced tumours. Transfer of genes that encode for the
expression of sst2 to sst-negative cancers may render these
tumours responsive to the currently available (radiolabelled
or cytotoxic) octapeptide somatostatin analogues (Benali et
al. 2000, Vernejoul et al. 2002, Guillermet et al. 2003).
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